Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis
Source
32 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis
Executed a 15-year, 910 critical IT MW triple-net powered land lease with a leading Frontier AI Lab at Corsicana, representing approximately $28…
–Quarterly Revenue of $195.3 million –
Full Page Monetization Live Across All NBCUniversal; Fox News Live 100%;
Record Third Quarter Revenue of $361 Million, Up 20% YoY
Net Asset Value of $12.64 Per Share as of September 30, 2026
FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026
- Net Income of $0.16 Per Diluted Share -
Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year